COMPLYADVANTAGE
7.12.2021 07:02:05 CET | Business Wire | Press release
Raisin DS’s servicing bank, Raisin Bank AG, is teaming up with ComplyAdvantage, the leader in AI-driven financial crime risk detection, to scale its anti-money laundering (AML) program. On the heels of launching as a cloud bank, Raisin Bank needed a provider that could keep pace with fast growth. The scalable solutions offered by ComplyAdvantage across customer screening and monitoring as well as transaction monitoring will support Raisin Bank’s Banking-as-a-Service offerings.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211206005505/en/
Raisin Bank offers banking services including customer and account management, payment processing and loans for international start-ups and financial service providers. The servicing bank has been part of Raisin DS since its acquisition by the fintech in 2019.
Stricter regulations require agile solutions
Money laundering represents a growing challenge for financial service providers and authorities worldwide. As a result, regulatory requirements for banks in the area of anti-money laundering have been strengthened. Financial services organizations are required to implement complex control mechanisms to identify users, verify them and react to changes at short notice. In addition to trained staff, banks are therefore dependent on the latest technologies to effectively monitor customer applications and transactions.
ComplyAdvantage simplifies the monitoring process
ComplyAdvantage's AML solutions are helping fast-growing fintechs to meet these challenges. The company combines integration via a modern API with the latest regulatory technology innovations. Its customer screening and monitoring and transaction monitoring solutions enable Raisin Bank to make continuous improvements to its anti-money laundering procedures. ComplyAdvantage’s intuitive user interfaces also facilitates the work of the bank's anti-money laundering officers. The system decides whether to stop suspicious payments or to review them in more detail based on rules with versatile settings and customization options.
Perfect complement for Raisin Bank's core banking system
Traditionally, AML solutions are integrated into a bank’s software infrastructure and are difficult to improve beyond their initial capabilities. In contrast, ComplyAdvantage's application is connected to Raisin Bank's cloud-native core banking system via a standardized API and thus can be further developed and scaled independently. This enables ComplyAdvantage to fit perfectly with Raisin Bank's technological approach.
Dominik Zühlke, Chief Product Officer at Raisin Bank, comments: "In ComplyAdvantage we have found a reliable and competent partner for Raisin Bank. With their adaptable solutions, we can continually advance the efficacy of our anti-money laundering efforts. Both our companies share a common understanding of what Banking-as-a-Service needs to be: a combination of modern technological products with customer centric consulting and support that focuses on making their businesses thrive.”
Charles Delingpole, Founder & CEO at ComplyAdvantage, adds: “Raisin Bank epitomizes the type of hypergrowth fintech solution provider that our AML solutions are ideally designed for. With API’s for easy integration, state-of-the-art tooling for AML analysts and the seamless onboarding of customers, our goal has always been to build intelligent solutions that help businesses like Raisin Bank to transact with trust so they can grow with confidence.”
ComplyAdvantage And Raisin Bank Partner To Combine Award-Winning AML Technology With State-Of-The-Art BaaS Solutions
#bankingasaservice BaaS #compliance #financialcrime #AML #antimoneylaundering
About Raisin Bank
Raisin Bank AG targets Europe's fast-growing fintech community with a wide range of innovative, tailored and reliable services. Raisin Bank offers expert advice and efficient Banking-as-a-Service solutions, particularly in the processing of loan portfolios and the receivables of selected borrowers. As a fronting and service bank with a full banking license, Raisin Bank supports the implementation of business models that require a banking license. Raisin Bank’s clients include fintechs like Raisin DS, Creditshelf and Exporo, as well as family offices and funds in the areas of loans, deposits, accounts and payment transactions, among others. The bank has been operating under the Raisin Bank AG name since April 2019 and is a wholly owned subsidiary of Raisin DS GmbH.
About ComplyAdvantage
ComplyAdvantage is the financial industry’s leading source of AI-driven financial crime risk data and detection technology. ComplyAdvantage’s mission is to neutralize the risk of money laundering, terrorist financing, corruption, and other financial crime. More than 700 enterprises in 75 countries rely on ComplyAdvantage to understand the risk of who they’re doing business with through the world’s only global, real-time database of people and companies. The company actively identifies tens of thousands of risk events from millions of structured and unstructured data points every single day.
ComplyAdvantage has four global hubs located in New York, London, Singapore and Cluj-Napoca and is backed by Ontario Teachers’, Index Ventures and Balderton Capital. Learn more at complyadvantage.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211206005505/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release
The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
